Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Enterprise Value (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Enterprise Value for 3 consecutive years, with -$124.2 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 18.6% to -$124.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$124.2 million through Dec 2025, up 18.6% year-over-year, with the annual reading at -$124.2 million for FY2025, 18.6% up from the prior year.
  • Enterprise Value for Q4 2025 was -$124.2 million at Inhibrx Biosciences, up from -$153.1 million in the prior quarter.
  • The five-year high for Enterprise Value was -$124.2 million in Q4 2025, with the low at -$277.9 million in Q4 2023.
  • Average Enterprise Value over 3 years is -$191.8 million, with a median of -$191.4 million recorded in 2024.
  • The sharpest move saw Enterprise Value skyrocketed 45.09% in 2024, then grew 17.78% in 2025.
  • Over 3 years, Enterprise Value stood at -$277.9 million in 2023, then surged by 45.09% to -$152.6 million in 2024, then grew by 18.6% to -$124.2 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$124.2 million, -$153.1 million, and -$186.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.